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Abstract
This paper examined neurocognitive functioning and its relationship to behavior treatment
response among youth with Tourette's Disorder (TD) in a large randomized controlled trial.
Participants diagnosed with TD completed a brief neurocognitive battery assessing inhibitory
functions, working memory, and habit learning pre- and post-treatment with behavior therapy
(CBIT, Comprehensive Behavioral Intervention for Tics) or psychoeducation plus supportive
therapy (PST). At baseline, youth with tics and Attention Deficit Hyperactivity Disorder (ADHD)
exhibited some evidence of impaired working memory and simple motor inhibition relative to
youth with tics without ADHD. Additionally, a small negative association was found between
antipsychotic medications and youth's performance speed. Across treatment groups, greater
baseline working memory and aspects of inhibitory functioning were associated with a positive
treatment response; no between-group differences in neurocognitive functioning at posttreatment were identified. Within the behavior therapy group, pre-treatment neurocognitive
status did not predict outcome, nor was behavior therapy associated significant change in
neurocognitive functioning post-treatment. Findings suggest that co-occurring ADHD is
associated with some impairments in neurocognitive functioning in youth with Tourette's
Disorder. While neurocognitive predictors of behavior therapy were not found, participants who
received behavior therapy exhibited significantly reduced tic severity without diminished
cognitive functioning.
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1. Introduction
Tourette's Disorder and Persistent Tic Disorders are neurodevelopmental disorders
characterized by involuntary motor movements and/or vocalizations (American Psychiatric
Association, 2013). These disorders (henceforth collectively referred to as Tourette's Disorder)
develop in childhood and affect approximately 0.4–1.6% of youth (Knight et al., 2012, Scahill et
al., 2014). In addition to tics, youth with Tourette's Disorder commonly experience co-occurring

psychiatric conditions [e.g., attention deficit hyperactivity disorder (ADHD), obsessivecompulsive disorder (OCD), and anxiety disorders] (Freeman et al., 2000, Specht et al., 2011),
functional impairment (Storch et al., 2007a), and reduced quality of life (Storch et al., 2007b,
Conelea et al., 2011). Thus, efficient and effective treatments are important for youth with
Tourette's Disorder. Traditionally, pharmacotherapy has been used to manage tic severity with
antipsychotic and alpha-2 agonist medications yielding moderate reductions in tic severity
(Weisman et al., 2012), although these medications are typically accompanied by adverse side
effects and only partial response (Scahill et al., 2006). Meanwhile, behavioral interventions
such as habit reversal training (HRT) and the Comprehensive Behavioral Intervention for Tics
(CBIT) (Woods et al., 2008) have demonstrated moderate-to-large reductions in tic severity
with no significant adverse effects or concerns of symptom substitution (Piacentini et al., 2010,
McGuire et al., 2014, Peterson et al., 2016). Despite the proven efficacy of behavior treatments
for tics, the neural mechanisms underlying their response remain largely unexamined and the
limited neurocognitive research to date has produced mixed findings among youth with
Tourette's Disorder.
Although the literature as a whole is inconsistent, dysfunction in inhibitory functioning, working
memory, and habit/procedural learning has been found across multiple studies of Tourette's
Disorder. For instance, several studies have found that youth with Tourette's Disorder have
significantly worse inhibitory functioning relative to unaffected controls across multiple tasks
(e.g., Go/No-Go task, Stop-Signal task, flanker task, visuospatial priming task, Stroop task)
(Swerdlow et al., 1996, Casey et al., 2002, Crawford et al., 2005). Meanwhile, other studies
have found no significant difference in inhibitory functioning between youth with tic disorders
and unaffected controls (Johannes et al., 2001, Goudriaan et al., 2006, Ray et al., 2006,
Roessner et al., 2007). Similarly, when working memory has been studied as part of executive
functions in Tourette's Disorder, findings are equivocal with some investigations reporting no
significant differences in working memory relative to unaffected controls (Channon et al., 2003,
Crawford et al., 2005) and others suggesting some indication of poorer performance (Chang et
al., 2007). With regard to habit or procedural learning, Marsh et al. (2007) found impairments in
habit learning on the Weather Prediction Task (WPT) between youth with Tourette's Disorder
and age-match unaffected controls, with the magnitude of impairment associated with tic
symptom severity. Although findings are inconsistent and contradictory likely due to differing
tasks and small sample sizes, some evidence suggests the possibility of deficits in inhibitory
functions, working memory, and habit learning among youth with Tourette's Disorder.
Given the sustained attention demand required of most neurocognitive tasks, co-occurring
ADHD may further complicate these results. For instance, co-occurring ADHD among youth
with Tourette's Disorder has been associated with greater neurocognitive dysfunction and
worse overall psychosocial functioning (Chang et al., 2007, Roessner et al., 2007, Greimel et
al., 2011). Indeed, in the largest neurocognitive study of youth with Tourette's Disorder to date,
Sukhodolsky et al. (2010) found that youth with tics + ADHD had deficits of sustained attention
whereas the tics-ADHD group more closely resembled unaffected control participants. This
finding is consistent with other studies indicating executive function-related inhibitory learning
dysfunction among participants with tics+ADHD compared to tics-ADHD (Ozonoff et al., 1998,
Channon et al., 2003). Taken together, these studies suggest that youth with Tourette's

Disorder may have deficits in inhibitory functions, working memory, and habit learning that may
be greater in the presence of co-occurring ADHD.
Aside from being implicated in the pathophysiology of Tourette's Disorder, inhibitory
functioning, working memory, and habit learning may influence therapeutic outcomes for youth
with Tourette's Disorder receiving behavior therapy. For instance, youth with Tourette's who
have greater dysfunction in inhibitory functions may have greater tic severity and/or greater
difficulty engaging in tic suppression tasks. Meanwhile, youth with deficits in working memory
may have greater difficulty retaining and/or recalling information presented in treatment
sessions. Similarly, youth with habit learning deficits may experience greater difficulty
implementing competing responses – a key feature of behavioral intervention.
Presently, only a handful of studies, all including adult participants, have directly explored the
interplay between neurocognitive factors and behavior therapy. First, Deckersbach et al.
(2006) examined predictors of response to behavioral interventions in 30 adults with Tourette's
Disorder and found that greater baseline inhibitory functioning on a visuospatial priming task
was associated greater treatment response. Second, a meta-analyses found greater ADHD
co-occurrence was associated with attenuated treatment response to behavior therapy
(McGuire et al., 2014), but other reports have not supported this findings (Sukhodolsky et al.,
2017). Third, O’Connor et al. (2008) examined changes in neurocognitive functioning before
and after a cognitive-behavioral treatment in 55 adults with Tourette's Disorder. Interestingly,
O’Connor et al. (2008) found some evidence of improvement in executive functions and skilled
motor performance after treatment. In contrast, a large trial of adults with Tourette's Disorder
found that change in tic symptom severity and treatment response were not associated with
neurocognitive performance on tests of inhibitory control, intellectual ability, or motor function
for either the behavior therapy or supportive therapy conditions (Abramovitch et al., 2017).
While no direct evaluation of the interplay between neurocognitive functioning and behavioral
interventions exists among youth with Tourette's Disorder, there is some suggestion from a
couple of small child studies that attention problems are associated with greater difficulty in tic
suppression among youth with persistent tics (Peterson et al., 1998, Himle and Woods, 2005).
Given the small sample sizes, inconsistent findings, and role of co-occurring ADHD found
among previous neurocognitive investigations, further research is needed to clarify the
possible impact of co-occurring ADHD in neurocognitive performance among youth with
Tourette's Disorder. Moreover, it is important to understand neurocognitive functioning as both
a predictor of treatment response and treatment outcome among youth with persistent tics.
Such investigations may also clarify whether neurocognitive functioning in Tourette's Disorder
may be malleable and responsive to intervention. Aside from advancing the etiological
understanding of Tourette's Disorder among youth, findings may also be important for
elucidating potential neural mechanisms of treatment response, identifying adjunct
neurocognitive interventions, and optimizing treatment recommendations for individual patients
based on neurocognitive predictors.
This study examined neurocognitive functioning in 126 youth with Tourette's Disorder at
baseline and posttreatment in a randomized controlled trial of behavior therapy and a
comparison condition (Piacentini et al., 2010). First, we examined whether youth with

Tics+ADHD differed in neurocognitive functioning relative to youth with Tics-ADHD at the
baseline assessment. Based on the phenomenological and neurocognitive distinctions
identified in smaller studies, we hypothesized that youth with Tics + ADHD would perform more
poorly on tasks of inhibitory functions, working memory, and habit learning. We also examined
the association between neurocognitive functioning and tic and ADHD symptom severity, and
presence of antipsychotic medication at baseline. Second, we examined whether baseline
inhibitory functioning, working memory, and habit learning predicted treatment response at
mid- and post-treatment for youth receiving behavior therapy. Based on the findings by
Deckersbach et al. (2006), we hypothesized that baseline inhibitory functioning would predict
treatment response to behavior therapy. Third, we explored whether neurocognitive
performance on tasks of inhibitory functions, working memory, and habit learning improved
after treatment for youth receiving behavior therapy.

2. Methods
2.1. Participants
Participants were part of the Comprehensive Behavioral Intervention for Tics Study, a multisite randomized controlled trial that compared the efficacy of a behavior intervention
(Comprehensive Behavioral Intervention for Tics, CBIT) versus an active comparison
treatment condition (Psychoeducation plus Supportive Therapy, PST) for the treatment of
youth with Tourette's Disorder. The background, rationale and procedures for the parent trial
have been described in detail elsewhere (Piacentini et al., 2010).
Eligible participants were required to have a primary diagnosis of Tourette's Disorder or
Persistent Motor Tics of moderate to greater severity, as measured by a Yale Global Tic
Severity Scale Total Tic Score greater than 13 (> 9 for children with chronic motor or vocal tics
only), English fluency, and IQ greater than 80. Co-occurring psychiatric conditions were
allowed unless the disorder required immediate treatment or change in current treatment.
Children receiving psychotropic medications for tics or other permissible psychiatric conditions
were eligible if the dose was stable for 6 weeks prior to enrollment, with no planned changes
during study participation. Exclusion criteria included an unstable medical condition, current
diagnosis of substance abuse/dependence, lifetime diagnosis of pervasive developmental
disorder, mania or psychosis, or four or more previous sessions of behavior therapy for tics.
Participants (N = 126) ranged in age from 9 through 17 years (mean age = 11.7 years, SD =
2.3 years); 99 (78.6%) were boys, 106 (84.1%) were white, and 93.7% (118) met criteria for
Tourette's Disorder. Overall, 36.5% of youth who entered the trial were receiving stable tic
medication, with 17% being on an antipsychotic medication. There were no significant
between-group differences in any baseline demographic or clinical characteristics, including
IQ, tic medication status, comorbidity profile, and baseline tic severity (Piacentini et al., 2010).
Sample sizes for each specific task are reported in Table 1.
Table 1. Sample characteristics and comparisons with co-occurring ADHD in youth with
Tourette's Disorder.

Total sample
N

Mean (SD)

Tics + ADHD
N

Mean (SD)

Tics-ADHD
N

Mean (SD)

t

p-value

d

INHIBITORY FUNCTIONING
Stroop Color-Word Test
− 0.05 0.96

0.01

32 44.22 (11.55) 92 45.88 (7.68)

0.92

0.36

0.19

124 49.96 (9.57)

32 47.16 (11.90) 92 50.93 (8.47)

1.95

0.05

0.40

124 51.02 (7.71)

32 49.03 (6.97)

1.71

0.09

0.35

Word Trial (T score)

125 47.22 (8.89)

32 47.28 (7.64)

Color Trial (T score)

124 45.45 (8.82)

Color-Word Trial (T score)
Interference (T score)

93 47.19 (9.33)

92 51.72 (7.87)

Stop-signal Task
% Accuracy Go

99

89.16 (12.10) 24 84.85 (12.37) 75 90.54 (11.76) 2.04

0.04

0.48

% Accuracy Stop

98

52.29 (9.40)

Go Reaction Time (ms)
Stop-signal Reaction Time (ms)

25 47.54 (8.86)

73 53.92 (9.07)

3.05

0.003*

0.71

101 738 (114)

25 691 (123)

76 753 (108)

2.43

0.02

0.55

93

22 227 (84)

71 250 (52)

1.51

0.14

0.38

244 (62)

Change-signal Task
% Accuracy Go

98

83.28 (13.76) 24 77.40 (14.90) 74 85.19 (12.90) 2.48

0.02

0.58

% Accuracy Stop

92

46.69 (11.50) 22 43.49 (11.27) 70 47.70 (11.46) 1.51

0.14

0.37

100 750 (132)

25 753 (120)

75 749 (137)

− 0.16 0.87

0.03

Inhibit Delay

99

409 (151)

24 377 (158)

75 419 (148)

1.21

0.23

0.28

Change-Signal Reaction Time

87

292 (85)

22 289 (102)

65 294 (80)

0.22

0.83

0.06

93 43.92 (7.10)

2.69

0.008*

0.55

Go Reaction Time (ms)

WORKING MEMORY
ACT Total Score

125 42.88 (7.58)

32 39.84 (8.21)

HABIT/PROCEDURAL LEARNING
Learning Coefficient (accuracy across
89
blocks)
Reaction Time Coefficient (speed
across blocks)

89

0.03 (0.13)

20

< − 0.01
(0.13)

69 0.03 (0.12)

1.11

0.27

0.16

− 85 (194)

20 − 159 (155)

69 − 63 (200)

1.97

0.05

0.50

111.52
(13.11)

1.96

0.05

0.40

FULL SCALE IQ
WASI FSIQ

126

110.10
(13.84)

33

106.09
(15.21)

93

Note: Tourette Disorder includes Persistent Tic Disorders; ADHD = Attention Deficit Hyperactivity
Disorder; ACT = Auditory Consonant Trigrams; WASI = Wechsler Abbreviated Scale of Intelligence.
*Indicates statistical significance, which was set at p < 0.003 for these comparisons due to Bonferroni
correction.

2.2. Measures
2.2.1. Symptom assessments
2.2.1.1. Anxiety Disorders Interview Schedule: Child and Parent Versions (ADIS–IV–C/P; Silverman
and Albano, 1996)

The ADIS–IV–C/P is a semi-structured psychiatric diagnostic interview administered separately
to parent and child, which was modified to include a tic disorders diagnosis module. A clinical
severity rating (CSR) of 4 or higher on a scale of 0–8 was considered indicative of a clinically
significant disorder. The instrument has demonstrated sound psychometric properties in
previous studies (Silverman et al., 2001, Wood et al., 2002).
2.2.1.2. Yale Global Tic Severity Scale (YGTSS; Leckman et al., 1989)

The YGTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are
rated separately from 0 to 5 on several scales including number, frequency, intensity,
complexity, and interference with the combined Total Tic Score ranging from 0 to 50. The
YGTSS possesses excellent psychometric properties with good internal consistency, excellent
inter-rater reliability, and excellent convergent and divergent validity (Leckman et al., 1989,
Storch et al., 2005). The change in the YGTSS Total Tic Score from baseline to mid-treatment
and from baseline to post-treatment served as a measure of treatment outcome.
2.2.1.3. Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS; DuPaul et al., 1998)

The ADHD-RS is an 18-item scale derived from ADHD diagnostic criteria in the Diagnostic and
Statistical Manual of Mental Disorders (4th edition). Each item is rated on a 4-point scale (0 =
not present; 3 = severe). The ADHD-RS produces 3 scores: Inattentive score (9 items),
Hyperactive score (9 items), and Total Score (18 items). The ADHD-RS Total Score has been
shown to be sensitive to medication effects in children with Tourette's Disorder (Scahill et al.,
2001).
2.2.1.4. Clinical Global Impression-Improvement Scale (CGI-I; Guy, 1976)

The CGI-I provides a global rating of clinical improvement from baseline with scores ranging
from 1 (very much improved) to 7 (very much worse). The CGI-I is well validated in treatment
studies of youth with PTD (Storch et al., 2011, Jeon et al., 2013). Consistent with prior studies,
a CGI-I rating of 1 (very much improved) or 2 (much improved) is considered to indicate a
positive treatment response.
2.2.2. Neurocognitive assessments
2.2.2.1. The Stroop Color Word Test (Golden, 1978)

The Stroop Color Word Test is designed to assess cognitive inhibitory functions. The task
consists of 3 consecutive trials: a word trial, a color trial, and a color-word trial. The number of
words identified correctly in each trial generates the trial score. The interference score was
calculated from the color-word trial and reflected the inhibition of a pre-potent response after
accounting for baseline processing speed.

2.2.2.2. The Stop-Signal Task (SST; Logan, 1994; Logan et al., 1997)

The SST is a computerized go/no-go paradigm that is used to assess aspects of inhibitory
control. The SST produces two different types of inhibition related outcomes. First, simple
motor inhibition is assessed and consists of go trials (e.g., press “1” when “X” appears or “2”
when “O” appears), and stop trials (e.g., when “X” or “O” appears followed by a change to a
red background, the stop signal, withhold previously learned response). The stop-signal
reaction time or speed of inhibition was the outcome variable of interest. Second, the stopchange condition is a variation of a stop-signal task that assesses motor response flexibility. In
this task, change trials are substituted for stop trials such that when the change signal (e.g.,
background changes to blue) is given, the subject is asked to perform an alternate response
(e.g., instead of pressing “1” at signal, press “3”) instead of simply withholding the previously
learned response as in the stop task. The change signal reaction time or the speed of inhibition
plus execution of an alternate response serves as the primary task-dependent variable.
2.2.2.3. Auditory Consonant Trigrams (ACT-child version; Stuss et al., 1987; Paniak et al., 1997)

The ACT evaluates verbal working memory and divided attention. Participants are verbally
presented with a consonant trigram (e.g., BXY) and then given an interference task (counting
backwards from a given number) to prevent explicit rehearsal. After varying time intervals (3, 9,
and 18 s), participants are asked to recall the trigram. Total number of correct consonants
retrieved correctly was used as the dependent variable. Average total scores for normative
children aged 9–15 range from 37.1 to 47.4 (Strauss et al., 2006).
2.2.2.4. The Weather Prediction Task (WPT; Knowlton et al., 1994)

The WPT is a measure of habit or procedural learning that requires gradual acquisition of
stimulus-response associations. Participants are asked to predict rain or sunshine based on
the presentation of a varying combination of a set of four different cards on a computer screen
by pressing one of two letters on the keyboard. Each card is independently and
probabilistically related to the outcomes, each of which occurs equally often. Participants
receive positive or negative feedback after each prediction via visual feedback on the
computer screen. The task consists of 90 trials lasting approximately 15 min. Accuracy (%
correct) and reaction time scores across six learning blocks were used as the outcome
variables. The task has been shown to distinguish healthy control patients from those with
striatal dysfunction such as Parkinson's disease and Tourette's Disorder (Knowlton et al.,
1996, March et al., 2004, Marsh et al., 2005). More recently, differing perspectives on the
validity of a dual memory system approach (implicit vs explicit) have questioned whether WPT
should be considered an implicit learning task (Newell et al., 2007). However, for the sake of
continuity with the tic research using this task (Marsh et al., 2004, Marsh et al., 2005), we refer
to the WPT as a habit learning task with these caveats in mind.
2.2.2.5. Wechsler Abbreviated Scale of Intelligence (WASI; Wechsler, 1999)

The WASI is a nationally standardized measure of intelligence for youth and adults, which is
an abbreviated reliable and valid version of the Wechsler Adult Intelligence Scale-3 edition

(WAIS-III). The full-scale intelligence quotient (FSIQ) was used to measure overall intelligence.
Individuals with a score ≥ 80 were deemed eligible to participate.
2.3. Procedure
Recruitment occurred across three clinical research centers: Johns Hopkins School of
Medicine (N = 41), the University of Wisconsin-Milwaukee (N = 40), and the University of
California Los Angeles (N = 45). Research protocols were approved by the local Institutional
Review Boards. All participants provided written informed consent and assent for parents and
youth, respectively. Afterward, participants completed a screening assessment to evaluate
inclusion and exclusion criteria that included the administration of the ADIS-IV-C/P and
YGTSS. Clinical assessments were completed by treatment-blind independent evaluators (IEs)
trained to reliability and were supervised using a structured protocol (Piacentini et al., 2010).
Eligible and interested participants returned for a baseline assessment that included YGTSS,
the ADHD-RS, and the neurocognitive assessment battery (Stroop, SST, ACT, and WPT).
Participants were randomized to receive either behavior therapy (CBIT: Comprehensive
Behavior Intervention for Tics) or the control condition (PST: Psychoeducation + Social
Support) immediately afterward. The behavior therapy condition consisted of a manualized
intervention with habit reversal training as its core component plus a parent-focused functional
intervention designed to identify and modify antecedent and consequent variables associated
with tic expression and maintenance (Woods et al., 2008). Both treatment conditions consisted
of eight sessions delivered over the course of 10 weeks. Participants were re-administered the
YGTSS, the neurocognitive battery and the CGI-I at post-treatment by independent evaluators
blinded to treatment condition (Piacentini et al., 2010). Participants were compensated for
participation in the assessment portion of the study, with treatment provided free of charge.
2.4. Reliability of neurocognitive assessment
Neurocognitive certification procedures were established to maintain protocol reliability. Senior
study personnel (SC) reviewed the initial videotaped administration of the neurocognitive
battery and scored assessment materials for each examiner at the three study sites. After the
initial certification, examiners were recertified on an annual basis following the same
procedures. Administration and scoring issues were resolved on cross-site study calls on an
ongoing and as-needed basis.
2.5. Analytic plan
First, descriptive statistics characterized the clinical and neurocognitive performance of the
sample, and Pearson correlations examined the relationship between neurocognitive scores at
baseline. Next, an independent sample t-test compared the baseline neurocognitive
performance across inhibitory functions, working memory, and habit learning between youth
with and without co-occurring ADHD. Pearson correlations examined the baseline association
of neurocognitive performance and tic symptom severity, ADHD symptom severity, and
antipsychotic medication status. Given the findings from previous studies noted above,
comparisons between youth with and without ADHD may not be considered preliminary.
Accordingly, a Bonferroni correction was applied to correct for multiple comparisons across

inhibitory functions, working memory, and habit learning variables (0.05/17 variables = 0.003).
Since there were no meaningful between treatment group differences on clinical or
neurocognitive characteristics at baseline, linear, step-wise, and logistic regression analyses
were used to examine whether baseline neurocognitive functioning predicted the change in
symptom severity at mid-treatment (Week 5) or post-treatment (Week 10) on the YGTSS and
CGI-I. Finally, a paired t-test examined the pre- to- post-treatment change in neurocognitive
functioning for the CBIT group, with an independent t-test comparing the pre- to- posttreatment change in neurocognitive functioning between treatment groups. Although the few
prior studies of adults with Tourette's Disorder have found some association between
neurocognitive factors and treatment response, no prior study has examined the relationship
between neurocognitive functioning and behavior therapy in children with Tourette's Disorder.
Given the exploratory nature of these comparisons, the statistical significance was set at 0.05
for tests examining the relationship of neurocognitive functioning and behavior therapy in youth
with Tourette's Disorder.

3. Results
Table 1 presents the baseline neurocognitive functioning for inhibitory functions (Stroop and
SST), working memory (ACT), habit learning (WPT), and IQ (WASI FSIQ) among youth
Tourette's Disorder with and without co-occurring ADHD. Table 2 presents the intercorrelations
between neurocognitive scores.
Table 2. Intercorrelations between neurocognitive tests at baseline for youth with chronic tic
disorders.
1

2

3

4

5

6

7

8

9

INHIBITORY FUNCTIONING
Stroop Color-Word Test
1. Word Trial (T score)
2. Color Trial (T score) 0.65**
3. Color-Word Trial (T
0.47** 0.64**
score)
4. Interference (T
score)

−
−
0.41**
0.14 0.07
Stop-signal Task

5. % Accuracy Go

−
0.17 0.29** 0.29**
0.02

6. % Accuracy Stop 0.04 0.10 0.26* 0.19 0.41**
7. Go Reaction Time
−
0.02
0.10 0.08 0.36** 0.81**
(ms)
0.03

10

11

12

13

14

15

16

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

8. Stop-signal
−
−
0.00
0.03 0.20 0.50** 0.79**
Reaction Time (ms) 0.05
0.01
Change-signal Task
9. % Accuracy Go

10. % Accuracy Stop

−
0.19 0.27** 0.26** 0.61** 0.48** 0.33** 0.14
0.04
−
0.09 0.20 0.16 0.33** 0.67** 0.59** 0.32** 0.66**
0.05

11. Go Reaction Time
−
−
−
0.01
0.07 0.49** 0.61** 0.43** 0.23* 0.68**
(ms)
0.09 0.07 0.03
12. Inhibit Delay
13. Change-Signal
Reaction Time

0.01 0.01 0.12 0.11 0.45** 0.66** 0.64** 0.25* 0.48** 0.87** 0.73**
0.02 0.02

−
−
−
0.21 0.40** 0.47** 0.17 0.34** 0.68** 0.11
0.08 0.06 0.07
WORKING MEMORY

14. ACT Total Score 0.13 0.24** 0.35** 0.31** 0.15 0.26** 0.05

−
−
−
0.25* 0.30**
0.17
0.16
0.07
0.18

HABIT LEARNING
15. Learning
−
−
−
−
Coefficient (accuracy 0.03 0.16 0.11
0.08 0.02 0.01 0.00 0.07 0.00
0.18
0.07
0.14 0.01 0.17
across blocks)
16. Reaction Time
Coefficient (speed
across blocks)

0.04

−
−
−
−
−
−
−
0.07
−0.12 0.02 0.00 0.17 0.09
0.14
0.04 0.05
0.16 0.04 0.04
0.08
0.15
FULL SCALE IQ

17. WASI FSIQ

0.33** 0.37** 0.32** 0.01 0.15 0.17 0.12 0.22* 0.07

−
0.06 0.02 0.13 0.06 0.04 − 0.09
0.03

Note: ACT = Auditory Consonant Trigrams; WASI = Wechsler Abbreviated Scale of Intelligence.
*p < .05.
**p < .01.

3.1. Baseline neurocognitive functioning with co-occurring ADHD
Youth with co-occurring ADHD had impaired working memory (p = 0.008) relative to youth
without ADHD. When examining inhibitory functions, youth with ADHD exhibited impaired
inhibitory functioning on certain aspects of simple motor inhibition as measured by the SST
(Accuracy Stop trials, p = 0.003), but minimal impairment on the Stroop and SST motor
response flexibility (p = 0.05–0.96, see Table 1).

3.2. Baseline neurocognitive correlates with tic symptom severity, ADHD symptom severity,
and antipsychotic medication
There were no associations between neurocognitive correlates and tic symptom severity (r = −
0.16 to 0.15, p = 0.13–0.96) or ADHD symptom severity (ADHD-RS; r = − 0.17 to 0.24, p =
0.02–0.95) at the baseline assessment. Meanwhile, there was a small negative association
between the presence of antipsychotic medication and a Stroop variable representing
processing speed (Stroop Word T-score, r = − 0.24, p < 0.006). However, there were no other
significant associations between neurocognitive variables antipsychotic medication status (r =
− 0.13 to 0.22, p = 0.02–0.91).
3.3. Predicting treatment response from baseline neurocognitive performance
Table 3 presents the baseline and change in neurocognitive performance between the two
treatment groups (CBIT: Comprehensive Behavior Intervention for Tics; PST: Psychoeducation
+ Social Support). Although there were minor baseline differences on aspects of inhibitory
functioning between groups (see Table 3), there were no significant differences on any other
neurocognitive factors or the presence of co-occurring ADHD (CBIT = 20, PST = 13, χ2 = 2.66,
p = 0.10, V = 0.15).
Table 3. Pretreatment and posttreatment neurocognitive scores for the CBIT and PST groups.
Pre-treatment
CBIT
(Behavior
therapy)
N

Mean
(SD)

Change at post-treatment
CBIT
(Behavior
therapy)

PST
(Education/Support)

N

Mean (SD)

d

p

N

Mean
(SD)

PST
(Education/Support)

N

Mean (SD)

d

p

INHIBITORY FUNCTIONING
Stroop Color-Word Test
Word Trial (T score)

60

48.53
(9.28)

65

46.00 (8.41)

0.28 0.11 54

− 1.28
(7.10)

58

− 3.66 (5.23)

0.38 0.05*

Color Trial (T score)

59

46.31
(9.77)

65

44.68 (7.85)

0.18 0.31 53

− 0.91
(6.71)

58

− 1.12 (5.54)

0.03 0.85

Color-Word Trial (T
score)

59

51.27
(10.52)

65

48.77 (8.52)

0.26 0.15 53

− 2.04
(9.48)

58

− 2.03 (9.22)

0.00 1.00

Interference (T score)

59

51.41
(6.55)

65

50.68 (8.66)

0.09 0.60 53

− 1.38
(8.43)

58

− 1.28 (11.45)

0.01 0.96

1.42
(10.28)

43

− 2.56 (11.53)

0.10 0.12

Stop-signal Task
% Accuracy Go

48

88.94
(12.05)

51

89.37 (12.26)

0.04 0.86 33

Pre-treatment
CBIT
(Behavior
therapy)
N

% Accuracy Stop

47

Mean
(SD)
52.04
(8.48)

45 247 (65)

CBIT
(Behavior
therapy)

PST
(Education/Support)

N

51

Go Reaction Time (ms) 49 729 (126) 52
Stop-signal Reaction
Time (ms)

Change at post-treatment

48

Mean (SD)

d

p

PST
(Education/Support)

Mean
(SD)

N

N

Mean (SD)

d

p

52.53 (10.25)

0.05 0.80 38

− 2.92
(11.07)

44

− 1.63 (7.46)

0.14 0.53

746 (103)

0.15 0.46 38

− 25
(114)

45

− 22 (82)

0.03 0.87

242 (59)

0.08 0.71 30 5 (58)

40

− 8 (65)

0.05 0.38

Change-signal Task
% Accuracy Go

48

82.15
(14.67)

50

84.38 (12.87)

0.15 0.43 36

0.76
(11.51)

42

− 0.83 (9.71)

0.01 0.51

% Accuracy Stop

43

45.00
(9.78)

49

48 (12.73)

0.26 0.19 34

− 1.49
(9.99)

42

− 3.89 (8.88)

0.26 0.27

Go Reaction Time (ms) 49 723 (129) 51

775 (131)

0.40 0.05* 39 −17 (126) 44

− 9 (90)

0.07 0.74

426 (152)

0.23 0.24 36

− 43
(154)

44

− 55 (103)

0.09 0.69

304 (72)

0.37 0.05 31 5 (62)

35

29 (69)

0.36 0.15

− 1.60
(6.08)

58

− 0.64 (4.96)

0.17 0.36

Inhibit Delay

48 391 (149) 51

Change-Signal Reaction
43 275 (86)
Time

43

WORKING MEMORY
ACT Total Score

60

42.68
(7.86)

65

43.06 (7.37)

0.05 0.78 53

HABIT LEARNING
Learning
Coefficient(accuracy
across blocks)

0.02
(0.12)

51

0.03 (0.13)

0.08 0.71 29

− 0.02
(0.15)

39

0.03 (0.19)

0.06 0.22

Reaction Time
− 121
Coefficient (speed across 38
(179)
blocks)

51

− 58 (201)

0.33 0.13 29

− 30
(242)

39

8 (311)

0.08 0.59

–

–

–

38

FULL SCALE IQ
WASI FSIQ

61

111.74
(13.55)

65

108.55 (14.04)

0.23 0.20 – –

–

Note: CBIT = Comprehensive Behavior Intervention for Tics; PST = Psychoeducation + Social Support;
ACT = Auditory Consonant Trigrams; WASI = Wechsler Abbreviated Scale of Intelligence.
*Indicates statistical significance, which was set at p < 0.05 for these comparisons due to their
exploratory nature.

Subsequently, baseline neurocognitive predictors of treatment response were examined
across treatment conditions for changes in tic severity at mid-treatment and post-treatment.
The step-wise regression model that consisted of all neurocognitive predictors was significant
(R2 = 0.11, F1,63 = 7.88, p = 0.007), and revealed that full scale IQ predicted reduction in tic
severity from baseline to mid-treatment in the full sample (β = 0.33, t1,63 = 2.81, p = 0.007).
Meanwhile, a step-wise regression model that included all neurocognitive predictors found that
working memory (ACT Total Score, β = 0.29, t1,58 = 2.35, p = 0.02) and response time on a
habit learning task (WPT reaction time, β = − 0.26, t1,58= − 2.11, p = 0.04)) predicted the
reduction in tic severity from baseline to post-treatment across groups (R2 = 0.14, F2,58 = 4.74,
p = 0.01). However, a linear logistic regression model with all neurocognitive predictors found
no significant predictors of baseline neurocognitive functioning and treatment response at
Week 10 (χ2 = 12.02, p = 0.85).
When examining baseline neurocognitive predictors of treatment response within the behavior
therapy group (CBIT), no single neurocognitive baseline predictor fulfilled the step-wise
regression criteria likely due to the small sample size. Meanwhile, a linear regression model
found no significant baseline neurocognitive predictors for either the change in tic severity from
baseline to mid-treatment (Week 5, R2 = 0.50, F18,9 = 0.49, p = 0.91) or from baseline to posttreatment (Week 10, R2 = 0.70, F18,9 = 1.15, p = 0.43). Furthermore, a logistic regression found
no significant predictors of baseline neurocognitive functioning and treatment response on the
CGI-I at Week 10 for the behavior therapy CBIT group (χ2 = 13.86, p = 0.74).
3.4. Neurocognitive changes within CBIT and between treatment groups
A paired t-test explored changes in neurocognitive functioning in the behavior therapy CBIT
group. Although findings suggested improvements in working memory after treatment (t52= −
1.92, p = 0.06, d = 0.26), this change was not significant, and there was no significant change
in neurocognitive functioning across inhibitory functions, working memory, or habit memory (p
= 0.10–0.69, d = 0.08–0.28). When comparing performance change between treatment
groups, no meaningful differences in the change in neurocognitive functioning were found
between treatment groups (see Table 3).

4. Discussion
Few studies have examined neurocognitive functioning among youth with Tourette's Disorder.
The present study is the first to examine the neurocognitive correlates of behavior treatment
outcome in a large sample of youth with Tourette's Disorder. The most robust neurocognitive
findings involved the impact of co-occurring ADHD, such that youth with Tics + ADHD
demonstrated poorer baseline verbal working memory and simple motor inhibition compared to
youth with Tics-ADHD. Specifically, the Tics + ADHD group exhibited lower accuracy on the
SST stop trials relative to youth with Tics-ADHD, which suggests the possibility of impulsivity
(commission errors). However, inhibitory functioning as measured by other SST variables and
Stroop performance mostly indicated that there was no difference between the two groups,
after controlling for multiple comparisons. Although a trend towards lower IQ and slower
response speed on a habit learning task also characterized the Tics+ADHD group at baseline,
this trend was also not statistically significant after controlling for multiple comparisons.

Collectively, these findings highlight the impact of comorbid ADHD on the neurocognitive
profile of pediatric Tourette's Disorder, which is particularly relevant given their common cooccurrence. The baseline associations of ADHD symptom severity with poorer working
memory, and simple motor inhibition are consistent with cognitive dysfunction, primarily
executive in nature, repeatedly identified in the ADHD literature (Pitcher et al., 2003; Mayes
and Calhoun, 2007; van der Oord et al., 2012). Notably, the current findings also reflect that
Tourette's Disorder on its own is not associated with meaningful neurocognitive impairment.
Many previous studies of Tourette's Disorder across the age spectrum have suggested a
profile of only subtle cognitive dysfunction, particularly in the case of tics uncomplicated by
comorbidity (Como, 2001; Chang et al., 2007; Sukhodolsky et al., 2010; Greimel et al., 2011).
Similarly, in adult Tourette's samples, several studies examining executive function have
shown no performance differences between Tourette's Disorder and unaffected controls
(Serrien et al., 2005, Thibault et al., 2009, Eddy and Cavanna, 2017, Thomalla et al., 2014).
Beyond the neurocognitive impairment associated with co-occurring ADHD, baseline
examinations revealed a small significant association between antipsychotic medication and
slower processing speed on the Stroop. Increased neurocognitive impairment among youth
taking antipsychotic medications is consistent with other research in children with
neuropsychiatric disorders (e.g., OCD; Lewin et al., 2014). While youth on antipsychotic
medications may represent a more severe group of pediatric CTD, there were no associations
between neurocognitive functioning and tic symptom severity at baseline. Thus, antipsychotic
medication and its side effect profile (e.g., sedation) may adversely affect neurocognitive
functioning in youth with CTD. Given the few number of youth taking antipsychotic medications
in this sample (13.5%), future research should further examine whether these effects would be
more robust in a larger medicated sample.
Although there were no baseline neurocognitive predictors significantly associated with
treatment response to behavior therapy, baseline working memory and habit learning response
time were associated with reductions in tic severity from baseline to post-treatment across
treatment conditions. While one prior study did find that a visuospatial priming task predicted
reductions in tic severity for adults with Tourette's Disorder receiving habit reversal therapy, the
primary therapeutic component of Comprehensive Behavior Intervention for Tics (Deckersbach
et al., 2006), developmental differences between children and adults with Tourette's Disorder
may influence potential predictors of therapeutic improvement. Specifically, adult with
Tourette's Disorder may represent a more severe and persistent form of the disorder
associated with greater neurocognitive impairment, which then may exert influence on
treatment outcomes. This is in line with pediatric tic studies that document absent or mild
behavioral dysfunction on neurocognitive measures (Como, 2001; Chang et al., 2007;
Sukhodolsky et al., 2010). Moreover, two other large studies in adults with Tourette's Disorder
found no relationship between performance on response inhibition tasks and treatment
outcome (Morand-Beaulieu et al., 2015, Abramovitch et al., 2017).
Beyond a lack of neurocognitive predictors, these results suggest that neurocognitive
performance as assessed by inhibitory functions, working memory, and habit learning
measures does not significantly change with treatment whether behavioral or supportive in
nature. Although research examining the stability of neurocognitive functioning is absent in

pediatric tic studies, two findings in adult with Tourette's Disorder have found behavior
treatment to be related to selective improvements in motor performance, which suggest some
degree of malleability in neurocognitive functioning (O'Connor et al., 2008, Lavoie et al., 2011).
However, these studies were conducted by the same research group using different tasks than
the ones used here. While specific aspects of neurocognitive functioning such as motor
performance may be more malleable relative to other constructs such as executive functioning
(O’Connor et al., 2008), it may be that the specific task and/or patient developmental level also
plays a role. Future research should consider investigating whether neurocognitive
impairments are stable across time in the absence of intervention.
While neurocognitive predictors of response to behavior therapy were not identified, youth
receiving Comprehensive Behavior Intervention for Tics exhibited significantly reduced tic
severity without any diminished cognitive functioning (Piacentini et al., 2010). This is important
because some parents and clinicians express concern that implementing behavioral strategies
for tics are likely to yield adverse effects on tics and increase the demand on children's
cognitive resources (Burd and Kerbeshian, 1987, Woods et al., 2010, Peterson et al., 2016).
Thus, these findings provide evidence that behavior therapy does not negatively impact
neurocognitive functioning, relative to a non-tic specific treatment. Indeed, our findings along
with other recent studies suggest that neither ADHD comorbidity nor its related neurocognitive
dysfunction significantly reduces response to behavior therapy (Abramovitch et al., 2017,
Sukhodolsky et al., 2017). Furthermore, positive treatment response to behavior therapy was
associated at 6-month post-treatment with improved social functioning and decreased anxiety,
disruptive behavior, and family strain (Woods et al., 2011). Thus, these findings offer further
support for recommendations of behavior therapy as a first-line intervention for Tourette's
Disorder (Murphy et al., 2013).
While not specific to the behavior therapy group, working memory and WPT response latency
predicted reductions in tic symptom severity across treatments. Specifically, poorer working
memory and slower WPT response time were related to worse clinical outcomes across
conditions. This suggests that better baseline working memory and processing speed have a
predictive relationship to reductions in tic symptom severity that may be unrelated to specific
treatment condition. While research into neurocognitive predictors of treatment response in
other disorders has been inconsistent, there has been some evidence to suggest that
executive functions such as working memory may function as a predictor of treatment
response in pediatric OCD (Flessner et al., 2010). However, due to our lack of a no-treatment
control group, we cannot entirely exclude the possibility that the association between baseline
neurocognition and treatment response was not meaningful, but rather reflected the natural
fluctuations of tics over time across both treatment conditions.
Despite clear strengths in methodology and sample size, a few limitations should be noted.
First, this study did not include a matched unaffected control group, which made it difficult to
assess the degree to which baseline neurocognitive performance in pediatric Tourette's
Disorder varied from the normal range of functioning. However, when baseline measures of
working memory (ACT) and inhibitory functioning (Stroop) were compared to published
normative data, comparisons showed that youth with Tourette's Disorder fell within the average
range of functioning (Strauss et al., 2006). In fact, inhibitory functions represented by the

Stroop Interference T-score was solidly in the average range (T-score range = 49–52) at
baseline regardless of ADHD comorbidity and remained unchanged with treatment. Second,
given the exploratory nature of the relationship between neurocognitive functioning and
behavior therapy in youth with Tourette's Disorder, we did not correct for multiple comparisons
for these analyses. Third, while the neurocognitive assessment battery was selected based on
the theorized dysfunction in pediatric Tourette's Disorder, it may be that other aspects of
neurocognitive functioning not captured in the present study serve as predictors of behavior
therapy and/or may be more influenced behavioral interventions. Future research should
examine additional neurocognitive constructs in pediatric Tourette's. Beyond this, it would be
beneficial to replicate the current findings with a different battery of neurocognitive tasks that
capture the same broad constructs, to provide further assurance that findings are not task
dependent.
In summary, this study found that co-occurring ADHD is associated with impaired cognitive
functioning, including poorer verbal working memory and aspects of simple motor inhibition, in
treatment-seeking youth with Tourette's Disorder. Although neurocognitive predictors of
behavior therapy were not identified, youth who received Comprehensive Behavior
Intervention for Tics exhibited significantly reduced tic severity without any diminishment in
cognitive functioning. This finding effectively counters concerns regarding the potentially
iatrogenic effects of behavior therapy on cognitive functioning; namely, that the cognitive
resources required to engage in treatment (e.g., real-time monitoring of tic urge and contingent
application of an incompatible behavior when urges are directed) may lead to greater
impairment than the tics themselves (Scahill et al., 2013). Across treatment groups, youth with
Tourette's Disorder demonstrating greater verbal working memory and response speed at
baseline exhibited greater reductions in tic symptom severity. Finally, findings suggest that
persistent tics may not be associated with appreciable neurocognitive dysfunction in youth,
and if subtle impairments are present, they are not likely to change with treatment. Future
research would benefit from the integration of multimodal evaluation of neurocognitive
functioning that includes behavioral data and functional neuroimaging to comprehensively
examine the neurocognitive mechanisms and predictors of treatment response in behavior
therapy for children with Tourette's Disorder.
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